Seaweed and soy foods are consumed daily in Japan, where breast cancer rates for postmenopausal women are significantly lower than in the West. Likely mechanisms include differences in diet, especially soy consumption, and estrogen metabolism. Fifteen healthy postmenopausal women participated in this double-blind trial of seaweed supplementation with soy challenge. Participants were randomized to 7 wk of either 5 g/d seaweed (Alaria) or placebo (maltodextrin). During wk 7, participants also consumed a daily soy protein isolate (2 mg isoflavones/kg body weight). After a 3-wk washout period, participants were crossed over to the alternate supplement schedule. There was an inverse correlation between seaweed dose (mg/kg body weight) and serum estradiol (E2) (seaweed-placebo ¼ y ¼ 0.28 3 dose 2 42.8; r ¼ 0.70; P ¼ 0.003), which was linear across the range of weights. Soy supplementation increased urinary daidzein, glycitein, genistein, and O-desmethylangolensin (P ¼ 0.0001) and decreased matairesinol and enterolactone (P , 0.05).
Introduction
Breast cancer incidence rates for Japanese women who migrate to the US rise dramatically after 10 y, increasing from 20/100,000 to 35/100,000 (1). Overall breast cancer incidence rates for resident Japanese-Americans are somewhat lower (103/100,000) (2) than the national U.S. average (118/100,000) (3) . These data support the hypothesis that lifestyle differences, especially dietary changes and related gene-nutrient interactions, are important in breast cancer susceptibility. Consumption of soy foods is the most commonly identified dietary difference, although recent meta-analyses suggest that eating soy foods may lower breast cancer risk by only ;20% (4, 5) .
Many studies have reported that higher levels of serum estradiol (E2) 10 are associated with an increase risk of developing breast cancer (6) and for disease recurrence (7) . Studies of Japanese postmenopausal breast cancer survivors have serum levels near the lower level of detection (8) compared with nearly 3-fold higher levels for U.S. postmenopausal breast cancer survivors (7) .
Japanese women who consume a traditional diet have 2-to 3-fold higher fecal excretion rates of E2 (9) , strongly suggesting that dietary factors and their effect on colonic bacteria may be critical in understanding differences in international breast cancer rates. Two large epidemiologic studies have reported a significant dose-response relationship between higher antibiotic use and breast cancer risk (10, 11) . A plausible mechanism for colonic bacterial influence on breast cancer would be through estrogen metabolism, by decreasing recirculation of E2 from the gastrointestinal tract. The same changes in colonic ecology might also be associated with increased efficiency in conversion of dietary soy isoflavones to phytoestrogens.
Seaweeds are typically part of most Japanese diets (12) . Brown seaweeds have unique insoluble indigestible fiber that has been shown to directly affect intestinal microflora (13, 14) . Seaweeds also have a higher binding affinity for estrogens than do land plant fibers (15) . Skibola (16) reported seaweed supplementation lowered serum E2 in 3 U.S. premenopausal women with menstrual dysfunction. Subsequent in vivo and in vitro studies confirmed a seaweed antiestrogenic effect (17) that may be independent of a fiber effect per se.
Brown seaweeds have no land equivalents in terms of their specific components of fiber (alginate), primary carotenoid (fucoxanthin), sulfated polysaccharides (fucoidan and laminarin), and polyphenol defense compounds, each of which have shown strong anticarcinogenic properties (18) (19) (20) .
This study focused on the ability of dietary Alaria esculenta, the American brown seaweed closely related to the popular Japanese seaweed Undaria pinnatifidia (Japanese wakame) (21) , to modulate serum hormone levels and urinary excretion of estrogen metabolites and phytoestrogens. A soy challenge was used to more closely approximate the diet consumed by Japanese women.
Materials and Methods

Study population
Participants were all healthy postmenopausal European-American women living in central Massachusetts. The University of Massachusetts Medical School Institutional Review Board approved the study. Consent forms were reviewed verbally and all participants gave written informed consent.
Inclusion criteria were: being postmenopausal (self-reported cessation of menstruation . 1 y prior to enrollment); no allergies to seaweed, soy, shellfish, or iodine; no current use of tobacco; no thyroid dysfunction or treatment within the previous 5 y; negative thyroid peroxidase antibodies as determined by screening; no hormone replacement therapy or for breast cancer survivors, no chemotherapy or radiation treatments within the preceding 6 mo, no history of cancer (other than breast cancer); no current gastrointestinal disorders or diabetes; omnivorous eating habits, including meat and dairy products . twice/wk; and no oral antibiotics, iodinecontaining medications, or corticosteroids treatment within the previous 3 mo. Women agreed to eat their normal diet, avoiding seaweeds and phytoestrogen-rich foods, restricting alcoholic intake to #2 drinks (24 g alcohol)/wk, and continuing habitual intake of vitamins, supplements, and medications during the study.
Women were recruited by word of mouth, physician referrals, and through responses to a newspaper article. Forty-eight postmenopausal women responded. Seven declined for lack of interest in the study protocol and 8 were excluded on the basis of thyroid-related issues [2 for abnormal serum thyroid stimulating hormone concentrations, 3 for high thyroid peroxidase antibodies (.191 U/L), and 3 for current or recent thyroid medications]. Thus, 33 women were enrolled into the study and provided baseline data.
Subsequently, 3 women dropped out of the study due to allergic reactions (rash and reactivated esophageal reflux) to seaweed (2) and naturopath advice (1) . Both allergic conditions resolved spontaneously following cessation of seaweed intake. At the end of the study, an additional 15 women were excluded from analyses for these reasons: tamoxifen use (4), antibiotic use during the study (4), resumption of menses (1), failure to take the supplements (1), and inability to follow protocol (consumed .2 drinks/wk) (5) . This left a final study sample of 15 women, among whom 6 were breast cancer survivors (Stage I, or II at diagnosis, but disease free at the time of the study) and 9 who had never been diagnosed with breast cancer.
Study design
Experimental design and dietary treatments. To minimize possible effects of season, all women began the study the same week in late October. The study utilized an unbiased, randomized, placebo-controlled crossover design. Prior to the first clinic visit, all eligible participants were assigned to a treatment group using a computer-generated random number table. Treatment arms were either 7 wk of 5 g/d seaweed powder (10 capsules) or 7 wk of 5 g/d maltodextrose in 10 identical gelatin capsules, followed by a 3-wk washout period and then crossed over to the opposite treatment arm. During wk 7, the women consumed a daily soy protein isolate (2 mg isoflavones/kg body weight) in addition to the 5 g/d seaweed or placebo. All capsules were taken with the last meal of the day.
Samples were collected a total of 6 times (blood samples and 48-h urine collection) throughout the study. To ensure the laboratory analysis was conducted without knowledge of treatments, each patient at each clinic visit was assigned a unique identification number.
Adherence to protocol A daily journal was provided for women to record any significant health changes, including new medications, and any phytoestrogen-rich foods or alcoholic beverages consumed. Urinary iodine was used to confirm adherence to the protocol during seaweed supplement periods.
Seaweed
Alaria esculenta (L.) Greville grows along the northeastern shores of North America. It was chosen for its low-iodine (95 mg/g) concentration (22) . A 5-g serving of Alaria harvested in the same area contains: 54.6 kJ, 0.9 g protein, 0.18 g fat, 2 g carbohydrate, 1.9 g fiber, 373 mg potassium, and 212 mg sodium (23) . The Alaria was collected in June from the Sally Islands by Maine Seaweed Company following standard collection protocols (22) .
Placebo
Maltrin M100 maltodextrin (Grain Processing) was used as placebo and 5 g/d provided 75.6 kJ.
Encapsulation
Mold and fungus levels were below detection limits. The seaweed was ground and encapsulated into gelatin capsules (Beehive Botanicals). No fillers or binders were added to the seaweed or placebo powder.
Soy protein isolate
A soy protein ingredient made with soy protein isolate [High Protein Nutritious Food Ingredient Powder (AB1.2 HG 20CA 29)] was provided by Solae, LLC (formerly Protein Technologies). It contained 1.43 mg/g total aglycone isoflavone equivalents. A dose of 2 mg isoflavones/kg body weight was calculated for each woman. The mean dose was 100 g/d dose of soy powder and provided 67 g of soy protein containing 85 mg genistein, 50 mg daidzein, and 8 mg glycitein.
Urine and blood collection Blood samples were drawn from fasting participants between 0630 and 1030 by venipuncture at a consistent time for each subject at baseline and at the end of each treatment period. Women collected 48-h urine specimens immediately preceding each visit. The collection jugs were stored in their refrigerators until the clinic visit. Urine volume was measured and sample aliquots were stored at 220°C until the end of the study and then at 280°C until analyses.
Laboratory analyses
Urinary estrogen metabolite analysis. Analyses of urinary 2-hydroxyestrogen (2-OHE) and 16a-hydroxyestrone (16aOHE 1 ) levels were completed at the Hackensack University Medical Center in a single batch, using the competitive solid-phase enzyme immunoassay from IMMUNA CARE (24) . The reported within-assay CV for this method ranges between 6 and 9% and the between-assay CV has been reported as 10%. It is important to note that C-2 antibody is 100% cross specific for 2-OHE 1 as well as 2-OHE 2 . Although 2-OHE 1 is the predominant C-2 metabolite found in women, the sum of both metabolites are measured (25) .
Urinary phytoestrogen analysis. Urinary phytoestrogen assays were conducted at the Cancer Research Center of University of Hawaii, Honolulu, HI. As previously described, the analysis used liquid chromatography-MS for phytoestrogens and a Cobas-autoanalyzer/ Jaffé-reaction-based assay for creatinine (26 Serum sex hormone analyses. Estrone (E1), E2, and sex hormonebinding globulin (SHBG) were analyzed at the University of Massachusetts laboratory of Dr. Christopher Longcope. Samples from a given individual were always assayed in the same batch. All samples were assayed in duplicate and the mean value was used for analysis. E1 was measured by RIA using kits provided by Diagnostic Systems Laboratories (DSL-8700). The lower limit of detection for E1 was 4.4 pmoI/L. Intra-and interassay CV were 2.1 and 5.9%, respectively. E2 was measured using DSL-4400 E2 double antibody RIA kit (Diagnostic Systems Laboratories). The lower limit of detection for this kit was 1.8 pmol/L. Intra-and interassay CV were 5.9 and 7.7%, respectively. SHBG was measured using DSL-7400 ACTIVE SHBG Coated-Tube Immunoradiometric Assay kit (Diagnostic Systems Laboratories) following the DSL protocol. The lower limit of detection for SHBG using this kit was 3 nmol/L. Intra-and interassay CV were 3.5 and 4.1%, respectively.
Statistical analyses
Study sample characteristics were compared by disease status using t tests for continuous variables and Fisher's exact test for categorical variables. To test the primary study hypotheses that seaweed influences estrogen metabolism and that the combination of seaweed plus soy (SeaSoy) would have a synergistic effect (the main effects for seaweed and soy, and a seaweed 3 soy interaction), we conducted a repeatedmeasures ANOVA using Proc Mixed in SAS. In these models, subject was fit as the repeated factor whereas treatment group (4 levels: placebo, seaweed, soy, and SeaSoy), sequence of treatment administration, disease status, disease status 3 treatment interaction, and age were fit as independent variables.
Individual models were run for 12 hormone-related dependent variables: serum measures of E1, E2, and SHBG, urinary estrogen metabolites 2-OHE, 16aOHE 1 , and the ratio of 2-hydroxyestrogen:16a-hydroxyestrone (2:16 ratio), and 2 groups of urinary phytoestrogens, the isoflavones: genistein, daidzein, glycitein, O-DMA, equol, and the lignans: secoisolariciresinol, matairesinol, enterolactone, and enterodiol. Results are presented as least square means (LSMeans; these are the covariate-adjusted means obtained from the mixed model) with 95% CI. Linear contrasts were created in Proc Mixed to test, relative to placebo, for the main effects of seaweed, soy, and SeaSoy, as well as the interaction between seaweed and soy. For the 3 main effects, the difference was calculated separately between the LSMeans for each treatment and placebo. To test for the interaction effect of SeaSoy, the difference was calculated as the LSMean for SeaSoy -the sum of the LSMeans for seaweed and soy. Significance was determined using a t test of the Ho: the difference ¼ 0 and a P-value , 0.05.
Many of the outcome variables were positively skewed; thus, data were log-transformed to meet the assumption of normality and then back-transformed for presentation and ease of interpretation. The phytoestrogens were measured as total amount excreted per day. Urine volume was measured for the entire 48-h collection and divided by 2 to obtain 24-h volume estimates used in the analyses. To rule out potential concerns about incomplete urine collections, analyses were conducted with both amount per day and amount per unit of creatinine, a metabolite that is excreted in fairly constant amounts day to day. As there were no material differences, we present only the per-day results.
The study design called for a single dose of seaweed (5 g/d) even though the weight of the participants ranged between 55 and 99 kg. To assess the potential for weight to modify the effect of seaweed, an exploratory correlation analysis was conducted using a seaweed dose variable (mg/kg).
In addition, we examined the effects of treatment on 2-OHE, 16aOHE 1 , and the ratio 2:16, comparing responses of women who were not equol producers with women who did produce equol by running separate mixed model analyses by equol production status. Equol producers were identified using the log 10 of the equol:daidzein ratio, where a value . 21.75 was classified as an equol producer (27) .
One woman who was an equol producer misunderstood the directions and when the soy supplement was added, she stopped taking the seaweed pills. Therefore, her values for SeaSoy are missing in all analyses. Estrogen metabolite values greater than the upper limit of test validity (36 mg/L) were not used (one participant). Three values for 16aOHE 1 were below the lower limit of test validity (0.5 mg/L) and were set to 0.4 mg/L for statistical analysis.
Results and Discussion
Based on changes in urinary iodine during the seaweed supplementation periods, adherence to the study protocol was very high. Fourteen of the participants had significant increases (mean ¼ 2.2 6 1.4 mmol/d; P ¼ 0.0001) during the seaweed period; all 15 women had increases during the SeaSoy supplementation period (2.0 6 1.0 mmol/d; P = 0.0001). A more detailed analysis of changes in iodine and thyroid hormone levels has been presented elsewhere (22) .
Demographic and lifestyle characteristics did not vary by disease status (breast cancer survivor or control) ( Table 1) . There was no significant effect on any of the serum or urinary endpoints for disease status or treatment arm.
Serum hormones. Serum hormones showed slight variations with the different supplements ( Table 2) . A small but significant decrease in E1 was noted during the SeaSoy period. SHBG decreased significantly after soy supplementation.
Seaweed supplementation was associated with an inverse correlation between seaweed dose (mg/kg body weight) and serum E2 and was linear across the range of weights (E2 change seaweed-placebo ¼ 0.28 3 dose -42.8; r ¼ 0.70; P ¼ 0.003) (Fig. 1) . Although there were also similar declines in E1 and SHBG with increasing seaweed dose, none of these were significant.
Although small by dried weight volume, seaweed has a water swelling capacity of ;10-fold, so a 5-g/d dose of seaweed composed of ;38% dried fiber would provide closer to 19 g/d additional dietary fiber volume when rehydrated during digestion. In vitro and in vivo studies of seaweed have reported increased water retention and fecal bulk and decreased colon transit time (28) . The insoluble indigestible component of seaweed fiber may decrease exposure of gastrointestinal conjugated estrogens for reabsorption by providing bulk and binding sites for adsorption (15) . An indirect mechanism for reducing serum E2 includes changes in the bacterial ecology of the colon. In vivo studies of a similar dietary seaweed (Undaria) report an 80% reduction in production of colonic b-D-glucuronidase (14), the enzyme needed to deconjugate E2 prior to enterohepatic recirculation. A third hypothesis is that the seaweed antiestrogenic effects are independent of a fiber effect. Skibola et al. (17) reported in vitro inhibition of E2 binding to estrogen receptor a and b in human luteinized granulosa cells. No specific mechanism was identified. Dietary seaweed may reduce E2 by all of these pathways.
Based on data from our study, the effective E2-lowering dose of seaweed would be ;75 mg/kg body weight. For the averagesized Japanese woman (54 kg) (29) , an effective daily dose of seaweed would be 3.8 g/d, a dose within the normal range of seaweed consumption in Japan (30) . An average American woman weighing over 20 kg more (76 kg) (31) would need to consume 5.3 g/d of seaweed to achieve the same effect. These estimates are consistent with the 5-7 g/d estimated effective by guest on July 31, 2017
jn.nutrition.org seaweed dose proposed by in vivo seaweed chemoprevention studies of mammary carcinoma (19, 20) .
Urinary phytoestrogens. Soy treatment was associated with increased urinary excretion of daidzein, glycitein, genistein, and O-DMA (P ¼ 0.0001) ( Table 3) . During the same period, matairesinol and enterolactone excretions tended to decrease (P ¼ 0.05). Seaweed alone did not affect these phytoestrogens. Five of the 15 women were classified as equol producers and results from only these 5 women are presented. In this subset of women, both equol and O-DMA increased with soy supplementation and even more with SeaSoy, suggesting a biomagnification of specific colon bacteria. The interactive effect of soy and seaweed on colonic microflora merits further study. Urinary equol excretion has been generally reported to be protective against breast cancer. In Japan, between 55 and 60% of the population produce equol after consuming soy foods, compared with only ;33% of people living in Western countries (27) . It is unclear if there might be physiologic benefits associated with increased equol levels for equol producers, although SeaSoy for these women was associated more favorable urinary estrogen metabolite profiles.
Nutritional epidemiologic studies in Japan rarely include seaweed, partly because it is hard to quantify, being consumed in both dried and rehydrated forms, includes a variety of different types of seaweeds, and because a hot water seaweed extract (Japanese dashi) broth is used to flavor many dishes so that the presence of seaweed is not obvious. Only 1 dietary study has included seaweed in its assessment of food variables associated with urinary phytoestrogen excretion and it did report a significant association between seaweed intake and equol production (32) .
Seaweed fiber reaching the colon may be prebiotic, providing substrate for specific bacteria associated with increased equol production (33) . The antibiotic properties of seaweeds may also influence population dynamics of colon bacteria, favoring healthy bacteria (34) .
Urinary estrogen metabolite data. There were significant increases in 2-OHE excretion and the 2:16 ratio during the soy and SeaSoy treatment periods ( Table 4) . In our small sample of 5 equol producers and 10 equol nonproducers, the results were not significantly different. However, the magnitude of the changes for women who were equol producers (n ¼ 5) were more impressive, with SeaSoy associated with a 58% increase in 2-OHE, a 40% decrease in 16aOHE 1 , and a 315% increase in the 2:16 ratio. The 16a-OHE 1 pathway is highly toxic, associated with genotoxic damage, stimulation of growth of anchorage independent breast cancer cells, irreversibly binding to estrogen receptors, and persistent hyperproliferation. A dietary intervention that could preferentially decrease estrogen metabolism from this pathway to the more benign 2-OHE pathway could have profound implications for breast cancer chemoprevention.
Our study is limited by its small size, which limits statistical power, as well as the uniform ethnic racial/ethnic composition typical of the population of central Massachusetts. Because this was a pilot study to determine whether a 5-g/d dose of seaweed would have any measurable effect on estrogen and phytoestrogen metabolism, changes in colonic microflora were not measured directly. Future studies should include direct measurement of changes in colonic bacteria. Finally, our estimate of seaweed dose was done post hoc, rather than prospectively, and needs to be explored further.
Although seaweed is only a seemingly small part of a Japanese diet, in seaweed-naive women, it lowered serum estrogens, increased favorable estrogen metabolism, and enhanced soystimulated conversion of phytoestrogens.
Many in vitro and in vivo studies have demonstrated anticarcinogenic activities of seaweeds, especially against breast cancer. The role of seaweed as a prebiotic catalyst for stimulating protective effects in phytoestrogen and estrogen metabolism is intriguing and provides a new food that may be important in dietary chemoprevention of breast cancer. 
